India has approved the QDENGA vaccine from Japan's Takeda Pharmaceutical, making it the first dengue vaccine to receive marketing approval. The decision marks the beginning of a new chapter in the country's battle against one of its most…
India has crossed an important public health milestone in its battle against dengue. Nearly six decades after the country's first recorded dengue epidemic, the Central Drugs Standard Control Organisation (CDSCO) on July 20 approved the QDENGA vaccine from Japan's Takeda Pharmaceutical, making it the first dengue vaccine to receive marketing approval. The decision marks the beginning of a new chapter in the country's battle against one of its most significant public health challenges. The QDENGA vaccine has shown promising results in clinical trials, and its approval is expected to help reduce the burden of dengue fever in India. The vaccine will be available in the market soon, and the government has promised to make it accessible to all citizens.